The United States and United Kingdom Announce Duty-Free Accord on Drugs.

The United Kingdom and the United States have finalized a key trade agreement that will maintain zero import taxes on UK medicine shipments going into the US market.

The Terms of the Accord

As part of the deal, the UK has committed to increase funding on pharmaceuticals through the National Health Service (NHS). This pledge secures that duties on these crucial products will be held at nothing for a period of 36 months.

This deal is in response to recent statements to significantly raise duties on patented drug imports, with potential rates discussed up to one hundred percent.

"This deal with the United Kingdom bolsters the international landscape for innovative medicines and introduces much-needed balance to American-British pharmaceutical trade," an announcement declared.

Commercial Importance

Pharmaceuticals are one of the Britain's largest export categories to the America, which is by far the primary destination for major companies like GSK and AstraZeneca.

Export figures indicate that in the 12 months prior to last September, the UK shipped medicines worth billions to the US. This amount accounted for a significant portion of total UK exports in that period.

"This guarantee secures employment, increases funding and facilitates the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary stated.

Key British Pledges

The agreement includes several specific changes from the United Kingdom:

• Revised Affordability Limit: The UK will increase the affordability limit at which it considers new medicines to be prohibitively costly by twenty-five percent.
• Boosted Medicine Funding: There is a target to raise overall health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
• Payback Limit: The percentage manufacturers must refund to the NHS to stay within budget will be capped at 15%. Last year, repayments were more than 20%.

Recent Tensions

The deal follows a ongoing dispute between the sector and the ministers over medicine costs and NHS adoption.

These tensions were exacerbated by assertions that US customers were charged significantly more for the equivalent treatments than consumers in the UK and Europe.

Recently, several large manufacturing plans in the UK have been delayed or abandoned, while major expansions have been directed toward American operations.

One official publicly accepted that the NHS had to invest a greater share on medicines, noting that its spending on drugs had shrunk as a share of its resources over the previous ten-year period.